Background: Hydroxychloroquine (HCQ) use is associated with less disease activity, flares, damage and improved survival in Systemic Lupus Erythematosus (SLE). However, its effect on patient reported health outcomes (PROs) such as quality of life (QOL) is not known. Methods: International data from Study on Outcomes of Lupus (SOUL) from 2,161 SLE patients were compared by HCQ use. Disease activity and damage were assessed using SELENA-SLEDAI and SLICC-ACR/SDI. QOL was evaluated using LupusPRO and Lupus Impact Tracker (LIT). Linear regression analyses were performed with LupusPRO summary scores health related HRQOL, non-health related NHRQOL and LIT as dependent and HCQ use as independent variable. Analyses were undertaken to test mediation of effects of HCQ use on QOL through disease activity. Results: Mean age was 40.512.8 years, 93% were women. Sixty-three (1363/2161) percent were on HCQ. On univariate analysis, HCQ use was associated with (a) better QOL (LupusPRO-HRQOL: b 6.19, 95% CI 4.15, 8.24, P0.001, LupusPRO NHRQOL: b 5.83, 95% CI 4.02, 7.64, P0.001) and less impact on daily life (LIT: b 9.37, 95% CI 12.24, 6.50, P0.001). On multivariate and mediational analyses, the effects of HCQ on QOL were indirectly and completely mediated through disease activity. Conclusions: HCQ use in SLE is associated with better patient reported health outcomes (LupusPRO-HRQOL and NHRQOL and impact on daily life), and the effects are mediated through disease activity. This information can facilitate patients and physician’s communication with decision-making regarding the use of HCQ for SLE management.
Does hydroxychloroquine improve patient reported outcomes in patients with lupus? / Meenakshi Jolly, Vinay Sehgal, Shilpa Arora, Desiree Azizoddin, Benzeeta Pinto, Aman Sharma, Herve Devilliers, Mitsuyo Inoue, Sergio Toloza, Ana Bertoli, Ivana Blazevic, Luis M Vila, Ioana Moldovan, Karina D Torralba, Davide Mazzoni, Elvira Cicognani, Sarfaraz Hasni, Berna Goker, Seminur Haznedaroglu, Josiane Bourre-Tessier, Sandra V Navarra, Ann Clarke, Michael Weisman, Daniel Wallace, Chi Chiu Mok. - In: LUPUS. - ISSN 0961-2033. - STAMPA. - 30:11(2021), pp. 1790-1798. [10.1177/09612033211033983]
Does hydroxychloroquine improve patient reported outcomes in patients with lupus?
Elvira Cicognani;
2021
Abstract
Background: Hydroxychloroquine (HCQ) use is associated with less disease activity, flares, damage and improved survival in Systemic Lupus Erythematosus (SLE). However, its effect on patient reported health outcomes (PROs) such as quality of life (QOL) is not known. Methods: International data from Study on Outcomes of Lupus (SOUL) from 2,161 SLE patients were compared by HCQ use. Disease activity and damage were assessed using SELENA-SLEDAI and SLICC-ACR/SDI. QOL was evaluated using LupusPRO and Lupus Impact Tracker (LIT). Linear regression analyses were performed with LupusPRO summary scores health related HRQOL, non-health related NHRQOL and LIT as dependent and HCQ use as independent variable. Analyses were undertaken to test mediation of effects of HCQ use on QOL through disease activity. Results: Mean age was 40.512.8 years, 93% were women. Sixty-three (1363/2161) percent were on HCQ. On univariate analysis, HCQ use was associated with (a) better QOL (LupusPRO-HRQOL: b 6.19, 95% CI 4.15, 8.24, P0.001, LupusPRO NHRQOL: b 5.83, 95% CI 4.02, 7.64, P0.001) and less impact on daily life (LIT: b 9.37, 95% CI 12.24, 6.50, P0.001). On multivariate and mediational analyses, the effects of HCQ on QOL were indirectly and completely mediated through disease activity. Conclusions: HCQ use in SLE is associated with better patient reported health outcomes (LupusPRO-HRQOL and NHRQOL and impact on daily life), and the effects are mediated through disease activity. This information can facilitate patients and physician’s communication with decision-making regarding the use of HCQ for SLE management.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
